参考文献/References:
[1]Bostrom P,Wu J,Jedrychowski MP,et al.A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis[J].Nature,2012,481(7382):463-468. [2]Lee P,Linderman JD,Smith S,et al.Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans[J].Cell Metab,2014,19(2):302-309. [3]Wu J,Bostrom P,Sparks LM,et al.Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human[J].Cell,2012,150(2):366-376. [4]Huh JY,Dincer F,Mesfum E,et al.Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans[J].Int J Obes(Lond),2014,38(12):1538-1544. [5]Park KH,Zaichenko L,Brinkoetter M,et al.Circulating irisin in relation to insulin resistance and the metabolic syndrome[J].J Clin Endocrinol Metab,2013,98(12):4899-4907. [6]Jedrychowski MP,Wrann CD,Paulo JA,et al.Detection and Quantitation of Circulating Human Irisin by Tandem Mass Spectrometry[J].Cell Metabolism,2015,22(4):734-740. [7]Loffler D,Muller U,Scheuermann K,et al.Serum irisin levels are regulated by acute strenuous exercise[J].J Clin Endocrinol Metab,2015,100(4):1289-1299. [8]Blizzard LD,Rioux BV,Pelech C,et al.Exercise-induced irisin release as a determinant of the metabolic response to exercise training in obese youth: the EXIT trial[J].Physiol Rep,2017,5(23):e13539. [9]Panati K,Suneetha Y,Narala VR.Irisin/FNDC5--An updated review[J].Eur Rev Med Pharmacol Sci,2016,20(4):689-697. [10]Han F,Zhang S,Hou N,et al.Irisin improves endothelial function in obese mice through the AMPK-eNOS pathway[J].Am J Physiol Heart Circ Physiol,2015,309(9):H1501-H1508. [11]Zhang M,Xu Y,Jiang L.Irisin attenuates oxidized low-density lipoprotein impaired angiogenesis through AKT/mTOR/S6K1/Nrf2 pathway[J].J Cell Physiol,2019,234(10):18951-18962. [12]Zhu D,Wang H,Zhang J,et al.Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses[J].J Mol Cell Cardiol,2015(87):138-147. [13]Lu J,Xiang G,Liu M,et al.Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice[J].Atherosclerosis,2015,243(2):438-448. [14]Deng W.Association of Serum Irisin Concentrations with Presence and Severity of Coronary Artery Disease[J].Medical Science Monitor,2016(22):4193-4197. [15]Ahmed E,Suwaidi JA,El-Menyar A,et al.Mortality Trends in Patients Hospitalized with the Initial Acute Myocardial Infarction in a Middle Eastern Country over 20 Years[J].Cardiology Research&Practice,2014(9):464323. [16]Reibel DK,Rovetto MJ.Myocardial ATP synthesis and mechanical function following oxygen deficiency[J].Am J Physiol,1978,234(5):H620-H624. [17]Kuloglu T,Aydin S,Eren M N,et al.Irisin:A potentially candidate marker for myocardial infarction[J].Peptides,2014(55):85-91. [18]Aydin S,Aydin S,Kobat MA,et al.Decreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology[J].Peptides,2014(56):141-145. [19]Aronis KN,Moreno M,Polyzos SA,et al.Circulating irisin levels and coronary heart disease:association with future acute coronary syndrome and major adverse cardiovascular events[J].International Journal of Obesity,2014,39(1):156-161. [20]Deng J,Zhang N,Wang Y,et al.FNDC5/irisin improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells for myocardial infarction[J].Stem Cell Res Ther,2020,11(1):228. [21]Xin T,Lu C.Irisin activates Opa1-induced mitophagy to protect cardiomyocytes against apoptosis following myocardial infarction[J].Aging(Albany NY),2020,12(5):4474-4488. [22]Tanai E,Frantz S.Pathophysiology of Heart Failure[J].Compr Physiol,2015,6(1):187-214. [23]Kalkan AK,Cakmak HA,Erturk M,et al.Adropin and Irisin in Patients with Cardiac Cachexia[J].Arq Bras Cardiol,2018,111(1):39-47. [24]Li R,Wu S,Wu Y,et al.Irisin alleviates pressure overload-induced cardiac hypertrophy by inducing protective autophagy via mTOR-independent activation of the AMPK-ULK1 pathway[J].Journal of Molecular and Cellular Cardiology,2018(121):242-255. [25]Liu X,Mujahid H,Rong B,et al.Irisin inhibits high glucose-induced endothelial-to-mesenchymal transition and exerts a dose-dependent bidirectional effect on diabetic cardiomyopathy[J].J Cell Mol Med,2018,22(2):808-822. [26]Yu Q,Kou W,Xu X,et al.FNDC5/Irisin inhibits pathological cardiac hypertrophy[J].Clinical Science,2019,133(5):611-627. [27]Shen S,Gao R,Bei Y,et al.Serum Irisin Predicts Mortality Risk in Acute Heart Failure Patients[J].Cellular Physiology and Biochemistry,2017,42(2):615-622. [28]Huo CJ,Yu X J,Sun Y J,et al.Irisin lowers blood pressure by activating the Nrf2 signaling pathway in the hypothalamic paraventricular nucleus of spontaneously hypertensive rats[J].Toxicol Appl Pharmacol,2020(394):114953. [29]Chen K,Zhou M,Wang X,et al.The Role of Myokines and Adipokines in Hypertension and Hypertension-related Complications[J].Hypertens Res,2019,42(10):1544-1551. [30]Zhang LJ,xie Q,Tang CS,et al.Expressions of irisin and urotensin II and their relationships with blood pressure in patients with preeclampsia[J].Clin Exp Hypertens,2017,39(5):460-467.
相似文献/References:
[1]王立民,刘有旺,王恩波,等.以大黄素为声敏剂介导声动力疗法对小鼠
动脉粥样硬化治疗作用的研究[J].医学信息,2018,31(06):58.[doi:10.3969/j.issn.1006-1959.2018.06.019]
WANG Li-min,LIU You-wang,WANG En-bo,et al.Study on the Effect of Emodin on the Treatment of Atherosclerosis in Mice[J].Medical Information,2018,31(02):58.[doi:10.3969/j.issn.1006-1959.2018.06.019]
[2]杨玉媛,刘有旺,李 腾,等.Th17细胞对动脉粥样硬化斑块易损性和斑块破裂的影响研究[J].医学信息,2018,31(18):53.[doi:10.3969/j.issn.1006-1959.2018.18.017]
YANG Yu-yuan,LIU You-wang,LI Teng,et al.Effect of Th17 Cells on Atherosclerotic Plaque Vulnerability and Plaque Rupture[J].Medical Information,2018,31(02):53.[doi:10.3969/j.issn.1006-1959.2018.18.017]
[3]陈玉媛,易爱姣,谭齐鸣,等.中青年冠状动脉粥样硬化患者颈动脉硬化的超声特征[J].医学信息,2019,32(02):175.[doi:10.3969/j.issn.1006-1959.2019.02.054]
CHEN Yu-yuan,YI Ai-jiao,TAN Qi-ming,et al.Ultrasound Characteristics of Carotid Atherosclerosis in Young and Middle-aged Patients with Coronary Atherosclerosis[J].Medical Information,2019,32(02):175.[doi:10.3969/j.issn.1006-1959.2019.02.054]
[4]郝冬冬,高 宇.C肽与动脉粥样硬化的相关性研究[J].医学信息,2019,32(09):28.[doi:10.3969/j.issn.1006-1959.2019.09.010]
HAO Dong-dong,GAO Yu.Correlation between C-peptide and Atherosclerosis[J].Medical Information,2019,32(02):28.[doi:10.3969/j.issn.1006-1959.2019.09.010]
[5]严文文,陈 然,金 平,等.老年患者颅内动脉粥样硬化性狭窄的分布和危险因素研究[J].医学信息,2019,32(09):78.[doi:10.3969/j.issn.1006-1959.2019.09.025]
YAN Wen-wen,CHEN Ran,JIN Ping,et al.Distribution and Risk Factors of Intracranial Atherosclerotic Stenosis in Elderly Patients[J].Medical Information,2019,32(02):78.[doi:10.3969/j.issn.1006-1959.2019.09.025]
[6]李慧丹,赵文鸽,王学惠.Nox4在同型半胱氨酸介导的动脉粥样硬化中作用的研究[J].医学信息,2019,32(15):45.[doi:10.3969/j.issn.1006-1959.2019.15.015]
LI Hui-dan,ZHAO Wen-ge,WANG Xue-hui.Research on the Role of Nox4 in Homocysteine-mediated Atherosclerosis[J].Medical Information,2019,32(02):45.[doi:10.3969/j.issn.1006-1959.2019.15.015]
[7]薛 一,孔莫维,高 宇.脂蛋白相关磷脂酶A2与冠心病的研究[J].医学信息,2019,32(12):53.[doi:10.3969/j.issn.1006-1959.2019.12.017]
XUE Yi,KONG Mo-wei,GAO Yu.Research on Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease[J].Medical Information,2019,32(02):53.[doi:10.3969/j.issn.1006-1959.2019.12.017]
[8]黄梦倩,张瑞恒,刘楚浩,等.影像组学在神经系统疾病中的应用研究[J].医学信息,2019,32(16):47.[doi:10.3969/j.issn.1006-1959.2019.16.015]
HUANG Meng-qian,ZHANG Rui-heng,LIU Chu-hao,et al.Application of Radiomics in Nervous System Diseases[J].Medical Information,2019,32(02):47.[doi:10.3969/j.issn.1006-1959.2019.16.015]
[9]高诗奇,邓代华,杨 静.成纤维细胞生长因子21抗动脉粥样硬化作用的研究[J].医学信息,2020,33(19):28.[doi:10.3969/j.issn.1006-1959.2020.19.009]
GAO Shi-qi,DENG Dai-hua,YANG Jing.Study on Anti-atherosclerosis Effect of Fibroblast Growth Factor 21[J].Medical Information,2020,33(02):28.[doi:10.3969/j.issn.1006-1959.2020.19.009]
[10]张 蕊,耿 佳,王雪梅.长链非编码RNA在内皮细胞损伤模型中的表达调控研究[J].医学信息,2020,33(22):71.[doi:10.3969/j.issn.1006-1959.2020.22.022]
ZHANG Rui,GENG Jia,WANG Xue-mei.Study on the Expression Regulation of Long Non-coding RNA in Endothelial Cell Injury Model[J].Medical Information,2020,33(02):71.[doi:10.3969/j.issn.1006-1959.2020.22.022]